The FDA began accepting applications for an expedited investigational new drug (IND) pilot designed to make early-phase clinical development faster. The program, described as part of “Operation Trialblazer,” incorporates public feedback on qualification criteria and aims to reduce regulatory friction that can slow U.S. Phase 1 starts. The pilot’s operational focus is on workflow and timing—specifically the review process and what “expedited” eligibility looks like for sponsors and proposed studies. For developers, it provides a concrete route to attempt to align U.S. early clinical timelines with those seen in markets like China and Australia. If adoption is broad, the pilot could affect trial initiation economics, especially for startups and mid-size biotechs that rely on rapid data generation to maintain investor momentum.